$12.9 Million Transaction Includes Approximately $3.4 Million of New Fundingand a $9.5 Million Full Cancellation of Outstanding Senior Notesand Extinguishment of Series B Preferred Shares The Company Also Established a $35 Million Equity Line of Credit WARRINGTON, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc.

。

(“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the closing of a private placement of (i) 16,099 shares of the Company’s Series C Convertible Preferred Stock, $0.001 par value (the “Series C Preferred Stock”), and (ii) warrants (the “Warrants”) to acquire up to the aggregate number of 3,440,631 additional shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), for aggregate gross proceeds of approximately $12.9 million, including $9.5 million through the cancellation and extinguishment of certain holders’ (x) outstanding (i) 10% senior convertible notes due January 2025, (ii) senior secured notes due June 2025, (iii) senior unsecured promissory notes due July 2025, and (iv) senior secured notes due July 2025, and (y) 5,500 shares of the Company’s Series B Convertible Preferred Stock.

（“Windtree”或“the Company”）（NasdaqCM:WINT）是一家专注于推进危重病和疾病早期和晚期创新疗法的生物技术公司，今天宣布停止私人配售（i）16099股公司C系列可转换优先股，面值0.001美元（“C系列优先股”），以及（ii）认股权证（“认股权证”），以获得总计3440631股公司普通股的额外股份，每股面值0.001美元（“普通股”），总收益约为1290万美元，其中包括通过取消和消灭某些持有人而获得的950万美元（x（i）2025年1月到期的10%优先可转换票据，（ii）2025年6月到期的优先担保票据，（iii）2025年7月到期的优先无担保本票，以及（iv）2025年7月到期的优先担保票据，以及（y）5500股公司B系列可转换优先股。

The Warrants will have an exercise price of $4.11 per share, subject to customary adjustments, will become exercisable on the six month and one day anniversary of the issuance date (the “Initial Exercisability Date”), and expire on the fifth anniversary of the Initial Exercisability Date. The Company filed a Current Report on Form 8-K with the Securities and Exchange Commission on July 22, 2024, with additional details of the transaction.

认股权证的行权价格为每股4.11美元，根据惯例进行调整，将在发行日期的六个月零一天（“初始行权日期”）行权，并在初始行权日期的五周年到期。该公司于2024年7月22日向美国证券交易委员会提交了表格8-K的最新报告，并提供了交易的其他详细信息。

The Company agreed to seek stockholder approval for the.

该公司同意寻求股东批准。